{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:11:11Z","timestamp":1753891871953,"version":"3.41.2"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is a highly heterogeneous hematological malignancy originating from B lymphocytes, with a high recurrence rate primarily due to drug resistance. 2-((1H-indol-3-yl)methyl)-3-((3-((1H-indol-3-yl)methyl)-1H-indol-2-yl)methyl)-1H-indole (LTe2), a tetrameric indole oligomer, possesses a wide range of anticancer activities through various mechanisms. Here, we aim to explore the anti-tumor efficiency and potential downstream targets of LTe2 in MM. Its bioactivity was assessed by employing MTT assays, flow cytometry, and the 5TMM3VT mouse model. Additionally, transcriptomic RNA-seq analysis and molecular dynamics (MD) experiments were conducted to elucidate the mechanism underlying LTe2 induced MM cell apoptosis. The results demonstrated that LTe2 significantly inhibited MM cell proliferation both <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>, and revealed that LTe2 exerts its effect by inhibiting the phosphorylation of AKT at the Thr308 and Ser473 sites. In summary, our findings highlight the potential of LTe2 as a novel candidate drug for MM treatment and provided a solid foundation for future clinical trials involving LTe2.<\/jats:p>","DOI":"10.3389\/fonc.2023.1269670","type":"journal-article","created":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:28:37Z","timestamp":1694741317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["LTe2 induces cell apoptosis in multiple myeloma by suppressing AKT phosphorylation at Thr308 and Ser473"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuanjiao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiacheng","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingmei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ye","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: A review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2017.05.012","article-title":"Pathobiology and diagnosis of multiple myeloma","volume":"33","author":"Brigle","year":"2017","journal-title":"Semin Oncol Nurs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","article-title":"Dynamic frailty risk assessment among older adults with multiple myeloma: A population-based cohort study","volume":"13","author":"Mian","year":"2023","journal-title":"Blood Cancer J"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50129","article-title":"Biology and therapy of multiple myeloma","volume":"210","author":"Joshua","year":"2019","journal-title":"Med J Aust"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0018-y","article-title":"The multiple myelomas - current concepts in cytogenetic classification and therapy","volume":"15","author":"Kumar","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3390\/nu11020467","article-title":"Inhibition of tumor growth by dietary indole-3-carbinol in a prostate cancer xenograft model may be associated with disrupted gut microbial interactions","volume":"11","author":"Wu","year":"2019","journal-title":"Nutrients"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau0159","article-title":"Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway","volume":"364","author":"Lee","year":"2019","journal-title":"Science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12915-014-0072-6","article-title":"Essential role of the cancer stem\/progenitor cell marker nucleostemin for indole-3-carbinol anti-proliferative responsiveness in human breast cancer cells","volume":"12","author":"Tin","year":"2014","journal-title":"BMC Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acs.orglett.5b00882","article-title":"Gene-inspired mycosynthesis of skeletally new indole alkaloids","volume":"17","author":"Lin","year":"2015","journal-title":"Org Lett"},{"key":"B12","doi-asserted-by":"publisher","first-page":"nwab144","DOI":"10.1093\/nsr\/nwab144","article-title":"Post-ingestion conversion of dietary indoles into anticancer agents","volume":"9","author":"Lin","year":"2022","journal-title":"Natl Sci Rev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.mrrev.2011.06.001","article-title":"Attenuation of multi-targeted proliferation-linked signaling by 3,3\u2019-diindolylmethane (DIM): from bench to clinic","volume":"728","author":"Banerjee","year":"2011","journal-title":"Mutat Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2019.01.031","article-title":"3,3\u2019-Diindolylmethane inhibits patient-derived xenograft colon tumor growth by targeting COX1\/2 and ERK1\/2","volume":"448","author":"Tian","year":"2019","journal-title":"Cancer Lett"},{"key":"B15","doi-asserted-by":"publisher","first-page":"132571","DOI":"10.1016\/j.foodchem.2022.132571","article-title":"Minor bioactive indoles from kimchi mirror the regioselectivity in indole-3-carbinol oligomerization","volume":"382","author":"Cheng Qian","year":"2022","journal-title":"Food Chem"},{"key":"B16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41419-021-03510-4","article-title":"Suppression of steroid 5alpha-reductase type I promotes cellular apoptosis and autophagy via PI3K\/Akt\/mTOR pathway in multiple myeloma","volume":"12","author":"Dou","year":"2021","journal-title":"Cell Death Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967811","article-title":"NAT10 acetylates BCL-XL mRNA to promote the proliferation of multiple myeloma cells through PI3K-AKT pathway","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.779562","article-title":"Acupuncture synergized with bortezomib improves survival of multiple myeloma mice via decreasing metabolic ornithine","volume":"11","author":"Ke","year":"2021","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13046-021-02220-1","article-title":"AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma","volume":"41","author":"Gu","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2004.07.019","article-title":"Visualization of 5T33 myeloma cells in the C57BL\/KaLwRij mouse: establishment of a new syngeneic murine model of multiple myeloma","volume":"32","author":"Alici","year":"2004","journal-title":"Exp Hematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-020-01634-z","article-title":"KNSTRN promotes tumorigenesis and gemcitabine resistance by activating AKT in bladder cancer","volume":"40","author":"Xiong","year":"2021","journal-title":"Oncogene"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2174\/1568009611313030002","article-title":"Diverse mechanisms of AKT pathway activation in human Malignancy","volume":"13","author":"Cheung","year":"2013","journal-title":"Curr Cancer Drug Targets"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"101100","DOI":"10.1016\/j.blre.2023.101100","article-title":"Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma","volume":"61","author":"Kegyes","year":"2023","journal-title":"Blood Rev"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-017-9707-8","article-title":"The proteasome and proteasome inhibitors in multiple myeloma","volume":"36","author":"Gandolfi","year":"2017","journal-title":"Cancer Metastasis Rev"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.tplants.2018.09.004","article-title":"Protein language: post-translational modifications talking to each other","volume":"23","author":"Vu","year":"2018","journal-title":"Trends Plant Sci"},{"key":"B27","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.molmed.2019.05.007","article-title":"PRMTs and arginine methylation: cancer\u2019s best-kept secret","volume":"25","author":"Jarrold","year":"2019","journal-title":"Trends Mol Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1517\/14728222.2011.547481","article-title":"Targeting NR4A1 (TR3) in cancer cells and tumors","volume":"15","author":"Lee","year":"2011","journal-title":"Expert Opin Ther Targets"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/cjoc.201800160","article-title":"Bioactive alkaloids from indole-3-carbinol exposed culture of daldiniaeschscholzii","volume":"36","author":"Lin","year":"2018","journal-title":"Chin J Chem"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2184.2003.00267.x","article-title":"Cell cycle and apoptosis","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-1924","article-title":"Chemopreventive agent 3,3\u2019-diindolylmethane selectively induces proteasomal degradation of class I histone deacetylases","volume":"70","author":"Li","year":"2010","journal-title":"Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13046-023-02699-w","article-title":"CircZNF215 promotes tumor growth and metastasis through inactivation of the PTEN\/AKT pathway in intrahepatic cholangiocarcinoma","volume":"42","author":"Liao","year":"2023","journal-title":"J Exp Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"107973","DOI":"10.1016\/j.envint.2023.107973","article-title":"Developmental defects induced by thiabendazole are mediated via apoptosis, oxidative stress and alteration in PI3K\/Akt and MAPK pathways in zebrafish","volume":"176","author":"Park","year":"2023","journal-title":"Environ Int"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.3390\/ijms24032809","article-title":"Interfering with the ubiquitin-mediated regulation of akt as a strategy for cancer treatment","volume":"24","author":"Paccosi","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0065679","article-title":"CSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site","volume":"8","author":"Zhuo","year":"2013","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0092-8674(00)81683-9","article-title":"The hallmarks of cancer","volume":"100","author":"Hanahan","year":"2000","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/09168451.2018.1549974","article-title":"AKT phosphorylation sites of Ser473 and Thr308 regulate AKT degradation","volume":"83","author":"Wei","year":"2019","journal-title":"Biosci Biotechnol Biochem"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.395","article-title":"The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia","volume":"23","author":"Gallay","year":"2009","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-020-05435-1","article-title":"Role of PI3K\/AKT pathway in cancer: the framework of Malignant behavior","volume":"47","author":"Jiang","year":"2020","journal-title":"Mol Biol Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1269670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T01:28:40Z","timestamp":1694741320000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1269670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,14]]},"references-count":40,"alternative-id":["10.3389\/fonc.2023.1269670"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1269670","relation":{},"ISSN":["2234-943X"],"issn-type":[{"type":"electronic","value":"2234-943X"}],"subject":[],"published":{"date-parts":[[2023,9,14]]},"article-number":"1269670"}}